Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

Published
18 March 2015
From
Motley Fool
Hepatitis C Drugs Will 'Strain Budgets': Study

New hepatitis C drugs promise cure rates above 90 percent, but could prove to be budget-busters for public and private health insurers, a new analysis finds.

Published
17 March 2015
From
WebMD
Gilead's hepatitis C drugs largely cost-effective in US - study

New hepatitis C drugs that shorten treatment times are largely cost-effective despite their hefty U.S. price tags, according to two new analyses.

Published
17 March 2015
From
Reuters
Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir

Almost all patients with hepatitis C virus (HCV) alone or HIV and HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin

Published
17 March 2015
By
Liz Highleyman
FDA to review re-submitted Bristol-Myers hepatitis C drug

U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.

Published
12 March 2015
From
Reuters
WHO issues its first hepatitis B treatment guidelines

WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries.

Published
12 March 2015
From
World Health Organization
Hepatitis C pills drive surge in U.S. drug costs: report

Highly effective but expensive new pills to treat hepatitis C drove a 13.1 percent increase U.S. prescription drug spending in 2014, the fastest rate of increase in more than a decade, according to Express Scripts.

Published
12 March 2015
From
Reuters
Re-infection due to ongoing risk probably the cause of HCV recurrence after SVR

Rates of hepatitis C virus (HCV) reoccurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent Conference on

Published
11 March 2015
By
Michael Carter
Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people

People with HIV and hepatitis C virus (HCV) co-infection who take sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C along with boosted protease inhibitor antiretroviral regimens may experience changes

Published
10 March 2015
By
Liz Highleyman
Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

Published
10 March 2015
From
Bidness

Filter by country